Jonathan Wolleben
Stock Analyst at Citizens
(4.58)
# 246
Out of 5,134 analysts
234
Total ratings
52.81%
Success rate
29.46%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $0.19 | - | 3 | Jan 30, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $527 → $745 | $487.32 | +52.88% | 15 | Jan 20, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $108 → $105 | $43.69 | +140.33% | 18 | Jan 8, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $95 → $140 | $102.83 | +36.15% | 13 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $21 → $45 | $20.70 | +117.39% | 16 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $141 → $167 | $102.53 | +62.88% | 6 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $87 → $120 | $71.41 | +68.04% | 11 | Dec 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $5.15 | +579.61% | 9 | Nov 14, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $11 → $10 | $5.73 | +74.52% | 10 | Nov 13, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $254 → $259 | $58.25 | +344.67% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $28 | $14.99 | +86.79% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $69 → $102 | $82.46 | +23.70% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $4.50 | +211.11% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $6.95 | +259.71% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $8.27 | +141.98% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $6.99 | +314.88% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.03 | +494.06% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $26.61 | +95.42% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.45 | +451.72% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.74 | +1,927.03% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.25 | +261.90% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $39.38 | -3.50% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $47.78 | +4.65% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $45.74 | +96.76% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $124.23 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $462.82 | +4.79% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $4.33 | +1,378.06% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $29.51 | -18.67% | 1 | May 12, 2023 |
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.19
Upside: -
Madrigal Pharmaceuticals
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $487.32
Upside: +52.88%
Crinetics Pharmaceuticals
Jan 8, 2026
Maintains: Market Outperform
Price Target: $108 → $105
Current: $43.69
Upside: +140.33%
Mirum Pharmaceuticals
Dec 19, 2025
Maintains: Market Outperform
Price Target: $95 → $140
Current: $102.83
Upside: +36.15%
DBV Technologies
Dec 17, 2025
Maintains: Market Outperform
Price Target: $21 → $45
Current: $20.70
Upside: +117.39%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Market Outperform
Price Target: $141 → $167
Current: $102.53
Upside: +62.88%
Structure Therapeutics
Dec 12, 2025
Maintains: Market Outperform
Price Target: $87 → $120
Current: $71.41
Upside: +68.04%
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.15
Upside: +579.61%
Savara
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.73
Upside: +74.52%
Spruce Biosciences
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $58.25
Upside: +344.67%
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $14.99
Upside: +86.79%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $69 → $102
Current: $82.46
Upside: +23.70%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $4.50
Upside: +211.11%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $6.95
Upside: +259.71%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $8.27
Upside: +141.98%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $6.99
Upside: +314.88%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.03
Upside: +494.06%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $26.61
Upside: +95.42%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.45
Upside: +451.72%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.74
Upside: +1,927.03%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.25
Upside: +261.90%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $39.38
Upside: -3.50%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $47.78
Upside: +4.65%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $45.74
Upside: +96.76%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $124.23
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $462.82
Upside: +4.79%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $4.33
Upside: +1,378.06%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $29.51
Upside: -18.67%